<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="pdc" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">pdc</book-part-id>
      <title-group>
        <title>Pyruvate Carboxylase Deficiency</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wang</surname>
            <given-names>Dong</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Neurology<break/>Columbia University<break/>New York, New York</aff>
          <email>dwang666888@gmail.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Vivo</surname>
            <given-names>Darryl</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Departments of Pediatrics and Neurology<break/>Columbia University <break/>Neurological Institute of New York<break/>New York, New York</aff>
          <email>dcd1@columbia.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>2</day>
          <month>6</month>
          <year>2009</year>
        </date>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="revised">
          <day>30</day>
          <month>7</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="pds" document-type="chapter">Pyridoxine-Dependent Epilepsy</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="rasa1-rel-dis" document-type="chapter">
<italic toggle="yes">RASA1</italic>-Related Disorders</related-object>
      <abstract id="pdc.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Pyruvate carboxylase (PC) deficiency is characterized in most affected individuals by failure to thrive, developmental delay, recurrent seizures, and metabolic acidosis. Three clinical types are recognized: type A (infantile form), in which most affected children die in infancy or early childhood; type B (severe neonatal form), in which affected infants have hepatomegaly, pyramidal tract signs, and abnormal movement and die within the first three months of life; and type C (intermittent/benign form), in which affected individuals have normal or mildly delayed neurologic development and episodic metabolic acidosis.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of PC deficiency rests on analysis of amino acids and organic acids and detection of deficiency of PC enzyme activity measured in fibroblasts. <italic toggle="yes">PC</italic> is the only gene in which mutation is known to cause PC deficiency.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Intravenous glucose-containing fluids, hydration, and correction of the metabolic acidosis are the mainstays of acute management. Correction of biochemical abnormalities and supplementation with citrate, aspartic acid, and biotin may improve somatic findings but not neurologic manifestations. Orthotopic liver transplantation may be indicated in some affected individuals. Anaplerotic therapies such as triheptanoin show some promise, especially regarding the neurologic manifestations, but need to be further evaluated.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Use of a high-carbohydrate and high-protein diet to prevent activation of gluconeogenesis.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Hospitalization for the management of fever, infection, dehydration or trauma; intensive proactive medical support to prevent dehydration, hypotension, hypoglycemia, and increasing metabolic acidosis.</p>
          <p><italic toggle="yes">Surveillance:</italic> Regular monitoring of serum lactate concentrations.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Fasting; the ketogenic diet.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>PC deficiency is inherited in an autosomal recessive manner. <italic toggle="yes">De novo</italic> somatic pathogenic variants have been reported. If both parents are carriers, sibs of an individual with PC deficiency have a 25% chance of inheriting both pathogenic variants and being affected, a 50% chance of inheriting one mutated gene and being carriers, and a 25% chance of inheriting both normal genes and not being carriers. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible by molecular genetic testing if both pathogenic variants have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="pdc.Diagnosis">
        <title>Diagnosis</title>
        <sec id="pdc.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Pyruvate carboxylase (PC) deficiency is suspected in individuals with failure to thrive, developmental delay, recurrent seizures, and metabolic acidosis.</p>
          <p>The three clinical presentations of PC deficiency:</p>
          <list list-type="bullet">
            <list-item>
              <p>Type A: infantile or North American form</p>
            </list-item>
            <list-item>
              <p>Type B: severe neonatal or French form</p>
            </list-item>
            <list-item>
              <p>Type C: intermittent/benign form</p>
            </list-item>
          </list>
        </sec>
        <sec id="pdc.Testing">
          <title>Testing</title>
          <p>
            <bold>Biochemical testing &#x02212; abnormalities by PC deficiency type</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Type A.</bold> Infantile-onset mild to moderate lactic acidemia; normal lactate-to-pyruvate ratio despite acidemia [<xref ref-type="bibr" rid="pdc.REF.robinson.2000">Robinson 2000</xref>, <xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>]</p>
            </list-item>
            <list-item>
              <p><bold>Type B.</bold> Increased lactate-to-pyruvate ratio; increased acetoacetate to 3-hydroxybutyrate ratio; elevated blood concentrations of citrulline, proline, lysine, and ammonia; low concentration of glutamine [<xref ref-type="bibr" rid="pdc.REF.nelson.2000.981">Nelson et al 2000</xref>, <xref ref-type="bibr" rid="pdc.REF.garc_acazorla.2006.121">Garc&#x000ed;a-Cazorla et al 2006</xref>, <xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>]</p>
            </list-item>
            <list-item>
              <p><bold>Type C.</bold> Episodic metabolic acidosis with normal citrulline plasma concentrations and elevated lysine and proline plasma concentrations [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>]</p>
            </list-item>
          </list>
          <p>
            <bold>Abnormalities by analyte</bold>
          </p>
          <p>Note: For each of the following analytes the abnormal values overlap among types A, B, and C. Normal values differ by laboratory.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Lactate and pyruvate.</bold> The lack of PC enzyme activity causes the accumulation of pyruvate in the plasma, which is subsequently converted into lactate by the enzyme lactate dehydrogenase, causing an elevated plasma concentration of lactic acid. Elevated blood lactate concentrations (5.5-27.8 mmol/L; normal range 0.5-2.2) are characteristically found in PC deficiency type A (2-10 mmol/L), type B (&#x0003e;10 mmol/L), and type C (2-5 mmol/L). Blood pyruvate concentrations are usually elevated in PC deficiency type B (0.14-0.90 mmol/L; normal range 0.04-0.13), resulting in an elevated lactate-to-pyruvate ratio (&#x0003e;20). The ratio is usually normal in PC deficiency type A and C (&#x0003c;20).</p>
            </list-item>
            <list-item>
              <p><bold>Amino acids.</bold> In serum and urine: high alanine, citrulline, and lysine; low aspartic acid and glutamine. Amino acid concentrations vary with the general metabolic state of the individual.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Hyperalaninemia as a result of pyruvate shunting</p>
                </list-item>
                <list-item>
                  <p>Hypercitrullinemia and hyperlysinemia caused by the block in the urea cycle secondary to a low aspartic acid</p>
                </list-item>
                <list-item>
                  <p>Low aspartic acid and glutamine as a result of deficiency in the oxaloacetate precursor</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Ketonemia.</bold> 3-hydroxybutyrate and acetoacetate concentrations are increased in blood. In PC deficiency type B, the ratio of acetoacetate to 3-hydroxybutyrate is increased, reflecting a low NADH-to-NAD ratio inside the mitochondria. Lack of oxaloacetate prevents the liver from oxidizing acetyl-CoA derived from pyruvate and fatty acids. The expanded acetyl-CoA pool results in hepatic ketone body synthesis [<xref ref-type="bibr" rid="pdc.REF.de_vivo.1977.1281">De Vivo et al 1977</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Hypoglycemia.</bold> Oxaloacetate deficiency limits gluconeogenesis. Note: Hypoglycemia is not a consistent finding despite the fact that PC is the first rate-limiting step in gluconeogenesis.</p>
            </list-item>
            <list-item>
              <p><bold>Hyperammonemia</bold> results from poor ammonia disposal and decreased urea cycle function.</p>
            </list-item>
            <list-item>
              <p>
                <bold>Cerebrospinal fluid (CSF)</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Elevated lactate and pyruvate concentrations</p>
                </list-item>
                <list-item>
                  <p>Markedly reduced glutamine concentration</p>
                </list-item>
                <list-item>
                  <p>Elevated glutamic acid and proline concentrations</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>PC enzyme assay</bold>. In PC deficiency, fibroblast PC enzyme activity is usually less than 5% of that observed in controls [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>]. Similar abnormalities are noted in lymphoblasts. Muscle PC activity is quite low in control tissue.</p>
            </list-item>
          </list>
          <sec id="pdc.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">PC</italic> is the only gene in which mutation is known to cause PC deficiency.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Deletion/duplication analysis.</bold> The usefulness of deletion/duplication testing has not been demonstrated, as no deletions or duplications of <italic toggle="yes">PC</italic> have been reported to cause pyruvate carboxylase deficiency.</p>
              </list-item>
            </list>
            <table-wrap id="pdc.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Pyruvate Carboxylase Deficiency</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PC</italic>
                    </td>
                    <td headers="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">95%&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon or whole-gene deletion/duplication</td>
                    <td headers="hd_h_pdc.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="pdc.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="pdc" object-id="pdc.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="pdc.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="pdc.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="pdc.TF.1.3">
                  <label>3. </label>
                  <p>The presence of mosaicism may complicate molecular testing; see <xref ref-type="sec" rid="pdc.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>, <xref ref-type="table" rid="pdc.T.selected_pc_variants">Table 2</xref>, and <xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al [2008]</xref>.</p>
                </fn>
                <fn id="pdc.TF.1.4">
                  <label>4. </label>
                  <p>Examples of variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="pdc.TF.1.5">
                  <label>5. </label>
                  <p><italic toggle="yes">PC</italic> promoters and coding region detects pathogenic variants in 95% of affected individuals including the most common <italic toggle="yes">PC</italic> pathogenic variants (<xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Ala610Thr</xref>, <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Arg631Gln</xref>, and <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Ala847Val</xref>).</p>
                </fn>
                <fn id="pdc.TF.1.6">
                  <label>6. </label>
                  <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="pdc.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> The diagnosis of PC deficiency rests on the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Detection of characteristic abnormalities in serum concentrations of amino acids, organic acids, glucose, and ammonia</p>
            </list-item>
            <list-item>
              <p>Deficiency of PC enzyme activity assayed in fibroblasts and other tissues</p>
            </list-item>
            <list-item>
              <p>Identification of <italic toggle="yes">PC</italic> pathogenic variants by sequence analysis</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="pdc.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="pdc.Clinical_Description">
          <title>Clinical Description</title>
          <p>Most individuals with pyruvate carboxylase (PC) deficiency present with failure to thrive, developmental delay, recurrent seizures, and metabolic acidosis. Hypoglycemia is an inconsistent finding.</p>
          <p>Three types of PC deficiency have been recognized, based on clinical presentation.</p>
          <p><bold>Type A (infantile form)</bold> is characterized by infantile onset with mild metabolic acidosis, delayed motor development, intellectual disability, failure to thrive, apathy, hypotonia, pyramidal tract signs, ataxia, nystagmus, and convulsions.</p>
          <p>Episodes of acute vomiting, tachypnea, and acidosis are usually precipitated by metabolic or infectious stress.</p>
          <p>Most affected children die in infancy or early childhood, although some may survive to maturity. Older individuals function at a lower-than-average level and need special care and schooling [<xref ref-type="bibr" rid="pdc.REF.carbone.1998.1312">Carbone et al 1998</xref>, <xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>].</p>
          <p><bold>Type B (severe neonatal form)</bold> was first described in France by <xref ref-type="bibr" rid="pdc.REF.saudubray.1976.717">Saudubray et al [1976]</xref>. Affected infants present with biochemical abnormalities, hypoglycemia, hyperammonemia, hypernatremia, anorexia, hepatomegaly, convulsions, stupor, hypotonia, pyramidal tract signs, abnormal movements (including high-amplitude tremor and dyskinesia), and bizarre ocular behavior.</p>
          <p>Motor development is severely retarded and affected individuals have intellectual disability [<xref ref-type="bibr" rid="pdc.REF.garc_acazorla.2006.121">Garc&#x000ed;a-Cazorla et al 2006</xref>, <xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>].</p>
          <p>Although the majority of affected infants die within the first three months of life [<xref ref-type="bibr" rid="pdc.REF.garc_acazorla.2006.121">Garc&#x000ed;a-Cazorla et al 2006</xref>], two are alive at ages nine and 20 years, likely because of mosaicism [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>] (see <xref ref-type="sec" rid="pdc.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>).</p>
          <p><bold>Type C (intermittent/benign form)</bold> is characterized by normal or mildly delayed neurologic development and episodic metabolic acidosis. Five affected individuals have been reported [<xref ref-type="bibr" rid="pdc.REF.van_coster.1991.1">Van Coster et al 1991</xref>, <xref ref-type="bibr" rid="pdc.REF.stern.1995.85">Stern et al 1995</xref>, <xref ref-type="bibr" rid="pdc.REF.vaquerizo_madrid.1997.663">Vaquerizo Madrid et al 1997</xref>, <xref ref-type="bibr" rid="pdc.REF.arnold.2001.519">Arnold et al 2001</xref>, <xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>]. The first individual described had normal mental and motor development at age 12 years despite several earlier episodes of metabolic acidosis [<xref ref-type="bibr" rid="pdc.REF.van_coster.1991.1">Van Coster et al 1991</xref>].</p>
          <p><bold>Brain MRI.</bold> Symmetric cystic lesions and gliosis in the cortex, basal ganglia, brain stem, or cerebellum; generalized hypomyelination; and hyperintensity of the subcortical fronto-parietal white matter were described in some individuals with type A.</p>
          <p>Ventricular dilation, cerebrocortical and white matter atrophy, or periventricular white matter cysts have been reported in some individuals with type B [<xref ref-type="bibr" rid="pdc.REF.garc_acazorla.2006.121">Garc&#x000ed;a-Cazorla et al 2006</xref>].</p>
          <p><bold>Magnetic resonance spectroscopy (MRS).</bold> Brain MRS shows high levels for lactate and choline, and low levels for <italic toggle="yes">N</italic>-acetylaspartate.</p>
          <p><bold>Pathophysiology.</bold> The glutamine-glutamate cycle in astrocytes requires a continuous supply of oxaloacetate provided by the reaction catalyzed by PC enzyme activity.</p>
        </sec>
        <sec id="pdc.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p><bold>Type A.</bold> Seven pathogenic variants (<xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Arg62Cys</xref>, <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Arg631Gln</xref>, <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Ala847Val</xref>, <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Val145Ala</xref>, <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Arg451Cys</xref>, <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Ala610Thr</xref>, and <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Met743Ile</xref>) have been identified in five individuals [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>].</p>
          <p><bold>Type B.</bold> Complex pathogenic missense variants, deletions, and splice donor site variants occur in homozygotes, compound heterozygotes, and individuals with mosaicism (see <xref ref-type="table" rid="pdc.T.selected_pc_variants">Table 2</xref>) [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>].</p>
          <p><bold>Type C.</bold> A heterozygous variant (<xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Ser266Ala</xref>) and somatic mosaic variant (<xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Ser705Ter</xref>) were observed in the first individual described [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>], and compound heterozygosity for the pathogenic variants <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Thr569Ala</xref> and <xref ref-type="table" rid="pdc.T.selected_pc_variants">Leu1137ValfsTer1170</xref> was observed in the second individual described [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>].</p>
          <p><bold>Mosaicism</bold> was found in five individuals [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>, <xref ref-type="table" rid="pdc.T.pc_genotypes_and_pc_level_and_acti">Table 3</xref> (type A: #6; type B: #2, #5, and #7; type C: #1)]. Four had prolonged survival; the fifth (type B: #7) died from unrelated medical complications.</p>
          <p><bold>Homozygous pathogenic variants.</bold> The deaths of the more severely affected individuals with type B correlated with homozygous variants, which produced very low amounts (2% and 3%) of fibroblast PC protein [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>, Table 3].</p>
        </sec>
        <sec id="pdc.Prevalence">
          <title>Prevalence</title>
          <p>In most populations, the incidence of PC deficiency is low (1:250,000).</p>
          <p>PC deficiency is more prevalent in particular ethnic groups:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Type A.</bold> Incidence is increased among the native North American Ojibwa, Cree, and Micmac tribes of the Algonquin-speaking peoples. The <xref ref-type="table" rid="pdc.T.selected_pc_variants">p.Ala610Thr</xref> pathogenic variant was identified in all 13 affected individuals of Ojibwa and Cree origin. In those populations the carrier frequency may be as high as 1:10 [<xref ref-type="bibr" rid="pdc.REF.carbone.1998.1312">Carbone et al 1998</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Type B.</bold> Incidence is increased in Europe (France especially, but also Germany and England).</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="pdc.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">PC</italic>.</p>
      </sec>
      <sec id="pdc.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="biotin" document-type="chapter"><bold>Biotinidase deficiency</bold></related-object> results from the inability to recycle endogenous biotin and to use protein-bound biotin from the diet. Biotin binds to propionyl-coenzyme A-carboxylase, pyruvate carboxylase (PC), beta-methylcrotonyl-CoA carboxylase, and acetyl-CoA carboxylase. Deficiency affects all biotinylated enzymes and can present in the neonatal period or later in infancy with neurologic symptoms such as lethargy, seizures with metabolic acidosis, hearing loss, alopecia, and perioral/facial dermatitis. It can be effectively treated with biotin.</p>
        <p>In the untreated state, profound biotinidase deficiency during infancy is usually characterized by neurologic and cutaneous findings that include seizures, hypotonia, and rash, often accompanied by hyperventilation, laryngeal stridor, and apnea. Older children may also have alopecia, ataxia, developmental delay, sensorineural hearing loss, optic atrophy, and recurrent infections. Individuals with partial biotinidase deficiency may have hypotonia, skin rash, and hair loss, particularly during times of stress.</p>
        <p>Biotinidase deficiency is caused by mutation of <italic toggle="yes">BTD.</italic> Individuals with profound biotinidase deficiency have lower than 10% of mean normal serum biotinidase activity; individuals with partial biotinidase deficiency have 10%-30% of mean normal serum biotinidase activity.</p>
        <p>Biotinidase deficiency is inherited in an autosomal recessive manner.</p>
        <p><bold>Pyruvate dehydrogenase complex (PDHC) deficiency</bold> results from deficiency of either one of three catalytic components (E1, E2, and E3) or the regulatory component of PDHC (pyruvate dehydrogenase phosphate phosphatase). The diagnosis of PDHC deficiency is suspected in individuals with lactic acidemia who have a progressive or intermittent neurologic syndrome including: poor acquisition or loss of motor milestones, poor muscle tone, new onset seizures, periods of incoordination (i.e., ataxia), abnormal eye movements, poor response to visual stimuli, and episodic dystonia. Blood and CSF lactate concentrations are elevated and are associated with elevations of blood and CSF concentrations of pyruvate and alanine. Blood glucose values are normal and decline only slowly with fasting because of increased pyruvate carboxylation and gluconeogenesis. Blood ketone bodies usually are not detectable, unlike PC deficiency. Also, unlike PC deficiency, PDH deficiency usually presents with a normal lactate-to-pyruvate ratio in plasma. Typically, the CSF lactate elevations are higher than those in the blood, giving rise to the term &#x0201c;cerebral lactic acidosis.&#x0201d;</p>
        <p>Brain MRI may show varying combinations of ventricular dilatation; cerebral atrophy; hydrocephaly; partial or complete absence of the corpus callosum; absence of the medullary pyramids; abnormal and ectopic inferior olives; symmetric cystic lesions; gliosis in the cortex, basal ganglia, brain stem, or cerebellum; or generalized hypomyelination.</p>
        <p>Brain MRS shows:</p>
        <list list-type="bullet">
          <list-item>
            <p>High lactate concentrations, giving rise to the term &#x0201c;cerebral lactic acidosis&#x0201d;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">N</italic>-acetylaspartate and choline concentrations consistent with hypomyelination</p>
          </list-item>
        </list>
        <p>PDHC enzyme activity assay, immunoblotting analysis, and sequence analysis of two of the genes known to be associated with this disorder (<italic toggle="yes">PDHA1</italic> [pyruvate dehydrogenase E1 deficiency] and <italic toggle="yes">DLAT</italic> [pyruvate dehydrogenase E2 deficiency]) can help make the diagnosis [<xref ref-type="bibr" rid="pdc.REF.dimauro.1999">DiMauro &#x00026; De Vivo 1999</xref>]. Most pathogenic variants involve the X-linked gene <italic toggle="yes">PDHA1,</italic> which encodes the E1 alpha subunit.</p>
        <p><bold>Respiratory chain disorder</bold> may result from pathogenic variants in nuclear genes or mitochondrial genes that encode any one of the five enzyme complexes. Lactate and pyruvate concentrations are elevated, and the lactate/pyruvate ratio is elevated, often above 20. Biopsied skeletal muscle may reveal ragged-red fibers, cytochrome <italic toggle="yes">c</italic>-oxidase negative fibers, and succinate dehydrogenase intensely positive fibers. These histologic abnormalities are commonly seen with pathogenic nuclear DNA variants causing intergenomic signaling defects and pathogenic mitochondrial DNA variants affecting protein synthesis genes. Brain MRI may reveal distinctive abnormalities, as described with <related-object link-type="booklink" source-id="gene" document-id="narp" document-type="chapter">Leigh disease</related-object> or mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (<related-object link-type="booklink" source-id="gene" document-id="melas" document-type="chapter">MELAS</related-object>) [<xref ref-type="bibr" rid="pdc.REF.dimauro.2008.91">DiMauro &#x00026; Schon 2008</xref>]. Nuclear gene variants are inherited in an autosomal recessive or dominant manner; mitochondrial DNA variants are inherited as maternal, non-Mendelian traits.</p>
        <p><bold>Krebs cycle disorders</bold> are rare and the enzymyopathies are partial. Lactate and pyruvate concentrations are elevated and the lactate/pyruvate ratio is normal. Urine organic acid profile may reveal distinctive elevation of fumaric acid or other Krebs cycle intermediates, reflecting the site of the enzyme deficiency.</p>
        <p><bold>Gluconeogenic defects</bold> may be aggravated clinically by fasting. Blood lactate, pyruvate, and alanine concentrations are classically elevated with clinical symptoms, and blood glucose concentration is low, indicating glycogen depletion and gluconeogenic pathway block. Ketone bodies are elevated, reflecting a physiologic response to fasting, stress, and hypoglycemia.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="ca5a-def" document-type="chapter"><bold>Carbonic anhydrase VA deficiency</bold></related-object> is suspected in children with neonatal, infantile, or early-childhood metabolic hyperammonemic encephalopathy combined with hyperlactatemia and metabolites suggestive of multiple carboxylase deficiency. The diagnosis is established in a proband with these metabolic findings and biallelic pathogenic variants in <italic toggle="yes">CA5A</italic>.</p>
      </sec>
      <sec id="pdc.Management">
        <title>Management</title>
        <sec id="pdc.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with pyruvate carboxylase (PC) deficiency, the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Blood, urine, and CSF measures of organic and amino acids; brain MRI and MRS analysis</p>
            </list-item>
            <list-item>
              <p>Evaluation by a pediatric neurologist skilled in metabolic and genetic disorders to confirm the diagnosis, guide the treatment, and determine the prognosis</p>
            </list-item>
            <list-item>
              <p>Genetic counseling for the parents regarding the risk of recurrence in future pregnancies</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="pdc.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment focuses on providing alternative energy sources, hydration, and correction of the metabolic acidosis during acute decompensation. Stimulating residual PC enzyme activity is an important goal for long-term stable metabolic status. Correction of the biochemical abnormality can reverse some symptoms, but central nervous system damage progresses regardless of treatment [<xref ref-type="bibr" rid="pdc.REF.dimauro.1999">DiMauro &#x00026; De Vivo 1999</xref>].</p>
          <p>&#x0201c;Anaplerotic therapy&#x0201d; is based on the concept that an energy deficit in these diseases could be improved by providing alternative substrate for both the citric acid cycle and the electron transport chain for enhanced ATP production [<xref ref-type="bibr" rid="pdc.REF.roe.2006.332">Roe &#x00026; Mochel 2006</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Citrate supplementation reduces the acidosis and provides substrate for the citric acid cycle [<xref ref-type="bibr" rid="pdc.REF.ahmad.1999.331">Ahmad et al 1999</xref>].</p>
            </list-item>
            <list-item>
              <p>Aspartic acid supplementation allows the urea cycle to proceed and reduces the plasma and urine ammonia concentrations but has little effect on the neurologic disturbances as the aspartate does not enter the brain freely [<xref ref-type="bibr" rid="pdc.REF.ahmad.1999.331">Ahmad et al 1999</xref>]. Lowering the body ammonia burden may mitigate the neurologic insult.</p>
            </list-item>
            <list-item>
              <p>Biotin supplementation is given to help optimize the residual PC enzyme activity but is usually of little use.</p>
            </list-item>
            <list-item>
              <p>Triheptanoin, an odd-carbon triglyceride, providing a source for acetyl-CoA and anaplerotic propionyl-CoA, has been tried in one individual with biotin-unresponsive PC deficiency type B with immediate reversal (&#x0003c;48 h) of major hepatic failure and full correction of all biochemical abnormalities [<xref ref-type="bibr" rid="pdc.REF.mochel.2005.305">Mochel et al 2005</xref>]. Triheptanoin provides C5-ketone bodies that can cross the blood-brain barrier, therefore providing substrates for the brain. Dietary intervention with triheptanoin is the only therapeutic approach that showed improvement of brain metabolism. However, this observation needs to be confirmed in additional patients.</p>
            </list-item>
            <list-item>
              <p>Orthotopic liver transplantation has reversed the biochemical abnormalities in two patients [<xref ref-type="bibr" rid="pdc.REF.nyhan.2002.143">Nyhan et al 2002</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="pdc.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>Educate parents about the factors that elicit a crisis and the early signs of decompensation.</p>
          <p>Carry an informational statement regarding the child's disorder and the appropriate treatment in an emergency setting.</p>
          <p>Minimize intercurrent infections as environmental stressors.</p>
        </sec>
        <sec id="pdc.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Individuals with PC deficiency are very brittle metabolically. Intensive medical support is indicated proactively to prevent dehydration, hypotension, hypoglycemia and increasing metabolic acidosis. Hospitalization is indicated for the management of fever, infection, dehydration or trauma. The ketogenic diet is an absolute contraindication, shown to worsen the acidosis into a life-threatening range.</p>
        </sec>
        <sec id="pdc.Surveillance">
          <title>Surveillance</title>
          <p>Monitor lactate levels regularly.</p>
        </sec>
        <sec id="pdc.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Fasting</p>
            </list-item>
            <list-item>
              <p>The ketogenic diet, which aggravates life-threatening metabolic acidosis</p>
            </list-item>
          </list>
        </sec>
        <sec id="pdc.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="pdc.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="pdc.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Pregnancy in a woman with PC deficiency has not been reported. However, women with the benign form (type C) could become pregnant; such a pregnancy should be closely monitored for any metabolic derangements including dehydration and acidosis.</p>
        </sec>
        <sec id="pdc.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Thiamine and lipoic acid could optimize PDHC activity, which could help reduce the plasma and urine pyruvate and lactate concentrations through an alternate route of pyruvate metabolism. Theoretically, this intervention could increase the acetyl-CoA pool and worsen the ketonemia.</p>
          <list list-type="bullet">
            <list-item>
              <p>Thiamine was tried in an individual with PC deficiency who was found to be responsive.</p>
            </list-item>
            <list-item>
              <p>Two sisters with PC deficiency, severe intellectual disability and motor retardation, and <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Leigh syndrome</related-object> improved clinically and biochemically after treatment with thiamine and lipoic acid. The precise molecular diagnosis in these cases is uncertain.</p>
            </list-item>
          </list>
          <p>Based on reports from the literature [<xref ref-type="bibr" rid="pdc.REF.nyhan.2002.143">Nyhan et al 2002</xref>, <xref ref-type="bibr" rid="pdc.REF.mochel.2005.305">Mochel et al 2005</xref>], it has been suggested that a combination of orthotopic liver transplantation and anaplerotic diet be used in order to obtain both (i) long-term metabolic stability and (ii) improvement/correction of brain energy metabolism, myelination, and neurotransmission.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="pdc.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="pdc.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Pyruvate carboxylase (PC) deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="pdc.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In most instances, the parents of a proband are heterozygotes and, therefore, carry a single copy of a pathogenic variant in <italic toggle="yes">PC</italic>.</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">De novo</italic> somatic pathogenic variants have been reported [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>] and may influence the phenotype and result in prolonged survival of the proband.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p>
              <list list-type="bullet">
                <list-item>
                  <p>If both parents are carriers, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
                </list-item>
                <list-item>
                  <p>If only one parent is a carrier (i.e., the PC deficiency occurred as the result of <italic toggle="yes">de novo</italic> somatic pathogenic variant in the proband in one allele and an inherited pathogenic variant in another allele), the sibs of a proband have a 50% chance of being asymptomatic carriers and a 50% chance of being unaffected and not carriers.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of a proband are obligate heterozygotes for a pathogenic variant.</p>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="pdc.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
          <p>Biochemical genetic testing for carrier status is not reliable.</p>
        </sec>
        <sec id="pdc.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="pdc.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">PC</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for PC deficiency are possible.</p>
        </sec>
      </sec>
      <sec id="pdc.Resources">
        <title>Resources</title>
      </sec>
      <sec id="pdc.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="pdc.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Pyruvate carboxylase (PC) [EC 6.4.1.1] is a biotin-dependent mitochondrial enzyme that plays an important role in energy production and anaplerotic pathways. PC catalyzes the conversion of pyruvate to oxaloacetate (<xref ref-type="fig" rid="pdc.F1">Figure 1</xref>).</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">PC</italic> contains 20 coding exons and four non-coding exons at the 5&#x02019;-UTR [<xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al 2008</xref>]. All four non-coding exons are involved in alternative splicing, resulting in three tissue-specific PC transcripts carrying the same coding region: variant 1 (4004 bp, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000920.3">NM_000920.3</ext-link>), variant 2 (3959 bp, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_022172.2">NM_022172.2</ext-link>), and variant 3 (4192 bp, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001040716.1">NM_001040716.1</ext-link>) (<xref ref-type="fig" rid="pdc.F2">Figure 2</xref>). Southern blotting of human genomic DNA showed that <italic toggle="yes">PC</italic> exists in a single copy and no pseudogenes are detected. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="pdc" object-id="pdc.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign variants.</bold> Many benign variants have been reported. Most are in the untranslated regions (UTR) and introns. Two benign variants with amino acid substitutions are known (<xref ref-type="table" rid="pdc.T.selected_pc_variants">Table 2</xref>).</p>
          <table-wrap id="pdc.T.selected_pc_variants" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">PC</italic> Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pdc.T.selected_pc_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                  <th id="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_pdc.T.selected_pc_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Benign</bold>
                  </td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.2286C&#x0003e;G</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.=&#x000a0;<sup>2</sup><break/>(Arg762Arg)</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_4" rowspan="16" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000920.3">NM_000920.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000911.2">NP_000911.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2619C&#x0003e;T</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.=&#x000a0;<sup>2</sup><break/>(Asn873Asn)</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2874G&#x0003e;T</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.=&#x000a0;<sup>2</sup><break/>(Gly958Gly)</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.227A&#x0003e;T</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.His76Leu&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1054G&#x0003e;T</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala352Ser&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_1" rowspan="11" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.184C&#x0003e;T</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg62Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.796T&#x0003e;A</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser266Ala</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.434T&#x0003e;C</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val145Ala</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1351C&#x0003e;T</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg451Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1705A&#x0003e;G</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr569Ala</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1828G&#x0003e;A</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala610Thr</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1892G&#x0003e;A</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg631Gln</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2114C&#x0003e;A</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser705Ter&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2229G&#x0003e;T</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Met743Ile</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2540C&#x0003e;T</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala847Val</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">3499-3500delCT</td>
                  <td headers="hd_h_pdc.T.selected_pc_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu1137ValfsTer1170&#x000a0;<sup>5</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="pdc.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="pdc.TF.2.2">
                <label>2. </label>
                <p>p.= designates that protein has not been analyzed, but no change is expected</p>
              </fn>
              <fn id="pdc.TF.2.3">
                <label>3. </label>
                <p>Presumed benign variants, but not yet reported in individuals with PC deficiency</p>
              </fn>
              <fn id="pdc.TF.2.4">
                <label>4. </label>
                <p>Indicates the mosaic state of this allele</p>
              </fn>
              <fn id="pdc.TF.2.5">
                <label>5. </label>
                <p>
                  <xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al [2008]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <table-wrap id="pdc.T.pc_genotypes_and_pc_level_and_acti" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>PC Genotypes and PC Level and Activity</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Case<break/>ID#</th>
                  <th id="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">PC<break/>Type</th>
                  <th id="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide&#x000a0;<sup>1</sup> Change</th>
                  <th id="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">PC Amount&#x000a0;<sup>3</sup></th>
                  <th id="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">PC Activity&#x000a0;<sup>4</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">1</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">C</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[796T&#x0003e;G; =] +<break/>[=; 2114C&#x0003e;A, =]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[S266A; =] +<break/>[=; S705*, =]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">86%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">1.9%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">B</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[1892G&#x0003e;A, =; =] +<break/>[=; 2493_2494delGT, =]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[R631Q, =; =] +<break/>[=; V831Vfs*832,=]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">8%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">3</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">B</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[321+1G&#x0003e;T] + [321+1G&#x0003e;T]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[V105_K107del] +<break/>[V105_K107del]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">3%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">4</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">B</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[806G&#x0003e;A] + [806G&#x0003e;A]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[R269Q] + [R269Q]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">2%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">5%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">5</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">B</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[467G&#x0003e;A; 496G&#x0003e;A; 1892G&#x0003e;A, =; 2540C&#x0003e;T, =] +<break/>[467G&#x0003e;A; 496G&#x0003e;A; =; =]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[R156Q; V166I; R631Q, =; A847V, =] +<break/>[R156Q; V166I; =; =]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">44%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">1.9%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">6</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">A</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[184C&#x0003e;T; 1892G&#x0003e;A ; 2540C&#x0003e;T] + [=; 1892G&#x0003e; A, =; 2540C&#x0003e; T, =]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[R62C; R631Q; 847V] + [=; R631Q, =; A847V, =]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">49%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">6%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">7</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">B</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[1892G&#x0003e;A; 2540C&#x0003e;T] +<break/>[1892G&#x0003e;A, =; 2540C&#x0003e;T, =]&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[R631Q; A847V] +<break/>[R631Q, =; A847V, =]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">17%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">17%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">8</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">C</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[1705A&#x0003e;G; =] +<break/>[=; 3409-3410delCT]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[T569A; =] +<break/>[=; L1137Vfs*1170]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">N/A</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">1%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">9&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">A</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[434T&#x0003e;C] + [434T&#x0003e;C]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[V145A] + [V145A]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Barely detectable</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">7%-25%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">10&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">A</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[1351C&#x0003e;T] + [1351C&#x0003e;T]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[R451C] + [R451C]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~100%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">7%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">11&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">A</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[1828G&#x0003e;A] + [1828G&#x0003e;A]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[A610&#x0003e;T] + [A610T]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~100%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">1%-4%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">12&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">A</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[2229G&#x0003e;T] + [2229G&#x0003e;T]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[M743I] + [M743I]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~100%</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">1%-4%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">13&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">B</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.[2493_2494delGT] +<break/>[2473+2-2473+5delTGCA]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">p.[V831Vfs*832] +<break/>[E825Gfs*846]</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~0</td>
                  <td headers="hd_h_pdc.T.pc_genotypes_and_pc_level_and_acti_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">1%-4%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Adapted from <xref ref-type="bibr" rid="pdc.REF.wang.2008.31">Wang et al [2008]</xref></p>
              </fn>
              <fn id="pdc.TF.3.1">
                <label>1. </label>
                <p>Nomenclature follows the recommendations for the description of sequence variants (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hgvs.org/mutnomen/recs.html">Recommendations for the description of sequence variants</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">Nomenclature for the description of sequence variants</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hgvs.org/mutnomen/checklist.html">Checklist for the description of sequence variants</ext-link>) [<xref ref-type="bibr" rid="pdc.REF.den_dunnen.2000.7">den Dunnen &#x00026; Antonarakis 2000</xref>, <xref ref-type="bibr" rid="pdc.REF.den_dunnen.2003.181">den Dunnen &#x00026; Paalman 2003</xref>]. The coding sequence is <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000920.3">NM_000920.3</ext-link>. Nucleotide +1 is the A of the ATG translation initiation codon. In brief, nucleotide changes in a single allele are listed between brackets as c.[434T&#x0003e;C] and changes in each allele as c.[434T&#x0003e;C] + [434T&#x0003e;C]. Nomenclature for mosaic cases is complex. Two different nucleotides found at one position on one chromosome are described as c.[2114C&#x0003e;A, =] (where &#x0201c;=&#x0201d; indicates the normal variant); more than two different substitutions are separated by a semicolon as c.[796T&#x0003e;G; =] + [=; 2114C&#x0003e;A, =]. Refer to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hgvs.org/mutnomen/examplesDNA.html">www.hgvs.org/mutnomen/examplesDNA.html</ext-link> for more information.</p>
              </fn>
              <fn id="pdc.TF.3.2">
                <label>2. </label>
                <p>Note: Changes are deduced based on the findings in DNA level. &#x0201c;0&#x0201d; indicates no protein; &#x0201c;=&#x0201d; indicates WT protein synthesized. The single-letter abbreviation for amino acids is used in this table; see <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation. Nomenclature for amino acid changes follows the same general format as described above for nucleotide changes.</p>
              </fn>
              <fn id="pdc.TF.3.3">
                <label>3. </label>
                <p>The PC /MCC +PCC ratios in individuals with PC are normalized to the ratio in normal control.</p>
              </fn>
              <fn id="pdc.TF.3.4">
                <label>4. </label>
                <p>The PC activity is expressed as the ratio of patient/control.</p>
              </fn>
              <fn id="pdc.TF.3.5">
                <label>5. </label>
                <p>#10 and #13 were reported by <xref ref-type="bibr" rid="pdc.REF.carbone.1998.1312">Carbone et al [1998]</xref> and <xref ref-type="bibr" rid="pdc.REF.carbone.2002.48">Carbone et al [2002]</xref>; #11 and #12 were reported by <xref ref-type="bibr" rid="pdc.REF.wexler.1998.579">Wexler et al [1998]</xref>.</p>
              </fn>
              <fn id="pdc.TF.3.6">
                <label>6. </label>
                <p>Nomenclature indicates the mosaic state of the two substitutions 1892G&#x0003e;A and 2549C&#x0003e;T in this allele. Together, with the other allele, these substitutions are more abundant than the &#x02018;=&#x02019; (wild-type) in this individual.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The protein consists of 1178 amino acids with a molecular weight of approximately 125 kd. It consists of a homotetramer of polypeptides, each covalently bound to a biotin molecule and processing both the catalytic and regulatory functions.</p>
          <p>PC (EC 6.4.1.1, PC) normally serves an anaplerotic function by replenishing the Krebs cycle and intermediates the conversion of pyruvate into oxaloacetate in response to elevated acetyl-coenzyme A levels (<xref ref-type="fig" rid="pdc.F1">Figure 1</xref>). The anaplerotic function of PC is important for the biosynthesis of neurotransmitters in the central nervous system, as well as energy metabolism. PC also controls the first step of hepatic gluconeogenesis and is important in lipogenesis.</p>
          <p>The enzyme is localized within the mitochondrial matrix in many tissues. Expression is highest in the liver, kidney, adipose tissue, pancreatic islets, and lactating mammary gland. Expression is moderate in brain, heart, and adrenal gland, and least in white blood cells and skin fibroblasts [<xref ref-type="bibr" rid="pdc.REF.jitrapakdee.1999.1">Jitrapakdee &#x00026; Wallace 1999</xref>].</p>
          <p><bold>Abnormal gene product.</bold> In some individuals with pathogenic missense variants, the protein is expressed but lacks activity or has only residual activity. Nonsense, splice-site, and frameshift variants identified to date result in quick degradation of mRNA. The mutagenesis studies of p.Ala610Thr, identified in Ojibwa with type A PC deficiency in a retroviral expression system, have shown that the pathogenic variant may affect the stability of the protein, resulting in decreased steady-state levels of expression, and affect the secondary structure of the protein during the import process, thereby inhibiting proper translocation into the mitochondria.</p>
        </sec>
      </sec>
      <sec id="pdc.References">
        <title>References</title>
        <sec id="pdc.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="pdc.Literature_Cited.reflist0">
            <ref id="pdc.REF.ahmad.1999.331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ahmad</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kahler</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artigas-Lopez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pappu</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steiner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millington</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate.</article-title>
                <source>Am J Med Genet</source>
                <volume>87</volume>
                <fpage>331</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10588840</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.arnold.2001.519">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griebel</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porterfield</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brewster</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Pyruvate carboxylase deficiency. Report of a case and additional evidence for the "mild" phenotype.</article-title>
                <source>Clin Pediatr (Phila)</source>
                <volume>40</volume>
                <fpage>519</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">11583052</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.carbone.2002.48">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Applegarth</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Intron retention and frameshift mutations result in severe pyruvate carboxylase deficiency in two male siblings.</article-title>
                <source>Hum Mutat</source>
                <volume>20</volume>
                <fpage>48</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">12112657</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.carbone.1998.1312">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacKay</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ling</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Douglas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rigat</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feigenbaum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haworth</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seargeant</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BH</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Amerindian pyruvate carboxylase deficiency is associated with two distinct missense mutations.</article-title>
                <source>Am J Hum Genet</source>
                <volume>62</volume>
                <fpage>1312</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9585612</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.de_vivo.1977.1281">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Vivo</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haymond</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leckie</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bussman</surname>
                    <given-names>YL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDougal</surname>
                    <given-names>DB</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Pagliara</surname>
                    <given-names>AS</given-names>
                  </name>
                </person-group>
                <year>1977</year>
                <article-title>The clinical and biochemical implications of pyruvate carboxylase deficiency.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>45</volume>
                <fpage>1281</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">412860</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.den_dunnen.2000.7">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>den Dunnen</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonarakis</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion.</article-title>
                <source>Hum Mutat</source>
                <volume>15</volume>
                <fpage>7</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">10612815</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.den_dunnen.2003.181">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>den Dunnen</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paalman</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Standardizing mutation nomenclature: why bother?</article-title>
                <source>Hum Mutat</source>
                <volume>22</volume>
                <fpage>181</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">12938082</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.dimauro.1999">
              <mixed-citation publication-type="book">DiMauro S, De Vivo DC. Diseases of carbohydrate, fatty acid and mitochondrial metabolism. In: Siegel J, ed. <italic toggle="yes">Basic Neurochemistry: Molecular, Cellular and Medical Aspects</italic>. Philadelphia, PA: Lippincott-Raven Publishers; 1999:841-63.</mixed-citation>
            </ref>
            <ref id="pdc.REF.dimauro.2008.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schon</surname>
                    <given-names>EA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Mitochondrial disorders in the nervous system.</article-title>
                <source>Annu Rev Neurosci.</source>
                <volume>31</volume>
                <fpage>91</fpage>
                <lpage>123</lpage>
                <pub-id pub-id-type="pmid">18333761</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.garc_acazorla.2006.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Cazorla</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabier</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touati</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chadefaux-Vekemans</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Pyruvate carboxylase deficiency: metabolic characteristics and new neurological aspects.</article-title>
                <source>Ann Neurol</source>
                <volume>59</volume>
                <fpage>121</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16278852</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.jitrapakdee.1999.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jitrapakdee</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Structure, function and regulation of pyruvate carboxylase.</article-title>
                <source>Biochem J</source>
                <volume>340</volume>
                <fpage>1</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">10229653</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.mochel.2005.305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mochel</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeLonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touati</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunengraber</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinman</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabier</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy.</article-title>
                <source>Mol Genet Metab</source>
                <volume>84</volume>
                <fpage>305</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">15781190</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.nelson.2000.981">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buse</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes.</article-title>
                <source>Diabetes</source>
                <volume>49</volume>
                <fpage>981</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">10866051</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.nyhan.2002.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nyhan</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khanna</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barshop</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Precht</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavine</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hart</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainline</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wappner</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Pyruvate carboxylase deficiency--insights from liver transplantation.</article-title>
                <source>Mol Genet Metab</source>
                <volume>77</volume>
                <fpage>143</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12359142</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.robinson.2000">
              <mixed-citation publication-type="book">Robinson BH. <italic toggle="yes">Lactic Acidemia: Disorders of Pyruvate Carboxylase and Pyruvate Dehydrogenase</italic>. New York, NY: McGraw-Hill; 2000.</mixed-citation>
            </ref>
            <ref id="pdc.REF.roe.2006.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mochel</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>29</volume>
                <fpage>332</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">16763896</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.saudubray.1976.717">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cathelineau</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Besson Leaud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroux</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>1976</year>
                <article-title>Neonatal congenital lactic acidosis with pyruvate carboxylase deficiency in two siblings.</article-title>
                <source>Acta Paediatr Scand</source>
                <volume>65</volume>
                <fpage>717</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">826106</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.stern.1995.85">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stern</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nayar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Depalma</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rifai</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Prolonged survival in pyruvate carboxylase deficiency: lack of correlation with enzyme activity in cultured fibroblasts.</article-title>
                <source>Clin Biochem</source>
                <volume>28</volume>
                <fpage>85</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7720232</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.van_coster.1991.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Coster</surname>
                    <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernhoff</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Vivo</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <year>1991</year>
                <article-title>Pyruvate carboxylase deficiency: a benign variant with normal development.</article-title>
                <source>Pediatr Res</source>
                <volume>30</volume>
                <fpage>1</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">1909777</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.vaquerizo_madrid.1997.663">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vaquerizo Madrid</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Val Sanchez de Leon</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez Alarcon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remon Alvarez-Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Congenital oculomotor apraxia and partial deficiency of pyruvate carboxylase.</article-title>
                <source>An Esp Pediatr</source>
                <volume>47</volume>
                <fpage>663</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9575131</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.wang.2008.31">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Braganca</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu Shih</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briones</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lang</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Vivo</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The molecular basis of pyruvate carboxylase deficiency: mosaicism correlates with prolonged survival.</article-title>
                <source>Mol Genet Metab</source>
                <volume>95</volume>
                <fpage>31</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18676167</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.wexler.1998.579">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wexler</surname>
                    <given-names>ID</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerr</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Du</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaung</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephenson</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lusk</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wappner</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higgins</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Molecular characterization of pyruvate carboxylase deficiency in two consanguineous families.</article-title>
                <source>Pediatr Res</source>
                <volume>43</volume>
                <fpage>579</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">9585002</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="pdc.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="pdc.Suggested_Reading.reflist0">
            <ref id="pdc.REF.h_berle.2013.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>H&#x000e4;berle</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and biochemical aspects of primary and secondary hyperammonemic disorders.</article-title>
                <source>Arch Biochem Biophys</source>
                <year>2013</year>
                <volume>536</volume>
                <fpage>101</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23628343</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.shah.2013.7423">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>GN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubbelke</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waheed</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoemaker</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sly</surname>
                    <given-names>WS</given-names>
                  </name>
                </person-group>
                <article-title>Targeted mutagenesis of mitochondrial carbonic anhydrases VA and VB implicates both in ammonia detoxification and glucose metabolism.</article-title>
                <source>Proc Natl Acad Sci USA.</source>
                <year>2013</year>
                <volume>110</volume>
                <fpage>7423</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23589845</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.van_karnebeek.2014.428">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>CDM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shevell</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moeschler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2014</year>
                <volume>111</volume>
                <fpage>428</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">24518794</pub-id>
              </element-citation>
            </ref>
            <ref id="pdc.REF.van_karnebeek.2014.453">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>CDM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sly</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvarinova</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaplito-Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santra</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shyr</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eydoux</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehman</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernard</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newlove</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ukpeh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakrapani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preece</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallance</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulter-Mackie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L-H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhavsar</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waheed</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasserman</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2014</year>
                <volume>94</volume>
                <fpage>453</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">24530203</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="pdc.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="pdc.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>30 July 2015 (bp/ctf) Revision: CA-VA added to Differential Diagnosis</p>
            </list-item>
            <list-item>
              <p>24 July 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 July 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>2 June 2009 (et) Review posted live</p>
            </list-item>
            <list-item>
              <p>7 March 2005 (ddv) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="pdc.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Diagrammatic representation of metabolic pathway affected by PC deficiency. The PC enzyme is indicated by the red oval; the dotted arrow lines represent absent pathways.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pdc-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="pdc.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p><italic toggle="yes">PC</italic> structure and three transcript variants. The coding exons of <italic toggle="yes">PC</italic> are represented by rectangles with different symbols and Arabic numbers on the top. The four untranslated exons (UEs) are labeled UE1-UE4 (top left). The arrows before UE1, UE2, and UE4 represent the transcription initiation sites. Three transcript variants are shown with the same coding region and different non-coding exons in the 5&#x02019;-UTR and the reference sequences for the three splice variants are given.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pdc-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
